Journal September 16, 2026 5 min read

How to Reconstitute Semaglutide

A laboratory-focused guide to reconstituting Semaglutide, covering the formal name, class, identifiers, and the research models in which it has been studied.

peptides-pro Editorial

Semaglutide is the formal name of a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used in research on type 2 diabetes and obesity [9]. It is also known by the synonym semaglutide sodium and is classified as an incretin mimetic. The compound is a 31-amino-acid acylated peptide with a molecular formula of C187H291N45O59 and a molecular weight of approximately 4113.6 g/mol. For laboratory use, Semaglutide is supplied as a lyophilized powder and must be reconstituted before experimental application.

The work centres on the glucagon-like peptide-1 receptor (GLP-1R), a class B G-protein-coupled receptor that mediates incretin signalling in pancreatic islets, the central nervous system, and peripheral tissues.

Research Studies

Semaglutide and metabolic syndrome in postpartum individuals with recent gestational diabetes

A randomized clinical trial is evaluating immediate postpartum semaglutide versus standard postpartum care in 226 individuals with recent gestational diabetes mellitus (GDM) [1]. The primary effectiveness outcome is the development of metabolic syndrome at 6 months postpartum. Participants then enter a 6-month maintenance phase in which continuation, discontinuation, or initiation of semaglutide reflects patient and clinician decisions [1]. This study is an effectiveness-implementation Hybrid Type 1 design, meaning it assesses both intervention effects and real-world integration [1].

Semaglutide and cardiometabolic risk in patients with schizophrenia and metabolic syndrome

A multicentre, double-blind, placebo-controlled randomized trial is testing adjunctive oral semaglutide 3 mg once daily added to treatment as usual in patients with schizophrenia on second-generation antipsychotics [2]. The study assesses 10-year cardiovascular risk (QRISK3), insulin resistance, lipids, weight, and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [2]. This population has a high burden of metabolic syndrome and elevated cardiovascular risk with few effective treatment options [2].

Semaglutide and muscle preservation in older adults with type 2 diabetes

A randomized, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care [3]. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6; secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [3].

Semaglutide and switching to zovaglutide in adults with obesity

The HORIZON-SWITCH-SZ study is evaluating the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity [4]. The main purpose is to assess outcomes after a switch from semaglutide to zovaglutide [4].

Semaglutide and alcohol use outcomes in patients with alcohol use disorder and obesity

A study is examining two doses of semaglutide (1.0 mg and 2.0 mg) versus placebo in patients with alcohol use disorder (AUD) and obesity (Ob) to assess whether these doses improve alcohol craving, stress, and alcohol use outcomes [5].

Semaglutide and weight loss in comparison with zenagamtide

A research study is investigating how well zenagamtide helps people with excess body weight lose weight compared to semaglutide [6]. The purpose is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide [6].

Semaglutide and early reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomized, parallel-controlled trial is comparing early reinitiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery) in 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery [7]. Participants are randomized to semaglutide 2.4 mg weekly or standard care for 24 months. Outcomes are assessed at 1 month, day of surgery, and 1, 3, 6, 9, 12, 18, and 24 months postoperatively. The hypothesis is that early reinitiation of semaglutide will be safe [7].

Semaglutide and heart and blood vessel health in postmenopausal obese breast cancer survivors taking aromatase inhibitors

A phase IV trial is studying whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor [8]. In this population, obesity raises the risk of heart and blood vessel problems. Semaglutide is approved by the United States Food and Drug Administration for weight loss and for lowering the risk of heart events in people with heart disease. The structured lifestyle support includes counseling on nutrition and physical activity with specific recommendations [8].

Semaglutide and analytical determination in pharmaceutical formulations and biological matrices

A comprehensive review reports that semaglutide is a potent long-acting glucagon-like peptide-1 receptor agonist with outstanding therapeutic efficacy for type 2 diabetes and obesity, and that its widespread clinical use has increased demand for analytical techniques to identify semaglutide in pharmaceutical formulations and biological matrices [9].

Semaglutide and treatment patterns among adult users in Denmark

A community pharmacy-based cross-sectional survey investigated semaglutide for weight management (SEMA-WM) treatment patterns among Danish adult users, noting that users may not follow the recommended treatment regimen [10]. The survey was conducted across 28 Danish community pharmacies between March and May 2025 [10].

Semaglutide and neuropsychiatric outcomes

A review reports that neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus and obesity, but whether risks differ across successive generations of incretin-based therapies remains uncertain [11].

Semaglutide and gallbladder-related adverse events

A pooled analysis of placebo-controlled STEP trials reports on gallbladder-related adverse events with semaglutide 2.4 mg [12].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.